Observational study of durvalumab for liver and bile duct cancer
Part of Cancer clinical trials.
This study looks at how well durvalumab (Imfinzi) works for people with liver or bile duct cancer. It follows your treatment as part of regular care to gather more information.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a confirmed cancer in the liver or bile ducts.
- You must be receiving or planning to receive treatment with durvalumab (Imfinzi).
- You must not be in another clinical trial for your cancer between diagnosis and the start of this study.
- You must not have had a second cancer before your liver or bile duct cancer diagnosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two immunotherapy drugs (rilvegostomig or durvalumab) combined with standard chemotherapy for people with bile duct or gallbladder cancer that has spread or cannot be removed. It aims to see if these combinations work better than chemo alone.
This trial tests a combination of two drugs, pemigatinib and durvalumab, in people with a certain type of advanced bile duct cancer that has a specific genetic change (FGFR2 fusion or rearrangement). The goal is to see if this combination can help when standard treatments have stopped working.
This trial tests the drug durvalumab in people with advanced liver cancer (HCC) that has spread beyond the liver and cannot be removed by surgery. It aims to see if durvalumab can help shrink tumors or slow the disease.
This trial tests a combination of a drug (durvalumab) that helps your immune system fight cancer, plus a special heat treatment applied inside the bile duct. It is for people with bile duct cancer that cannot be removed by surgery and who need a stent to open the bile duct.
This trial tests combining two treatments: durvalumab (an immunotherapy drug) and histotripsy (a focused ultrasound that breaks down tumor tissue) for people with a type of liver cancer called intrahepatic cholangiocarcinoma. It aims to see if adding histotripsy after initial chemotherapy helps control the cancer better.
This trial tests giving durvalumab (an immunotherapy drug) together with chemotherapy before surgery for bile duct or gallbladder cancer. The goal is to see if this combination shrinks tumors and improves outcomes for patients whose cancer is considered high-risk but still removable.
Hear when a new Hepatobiliary Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.